CO VALACYCLOVIR TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE)

から入手可能:

COBALT PHARMACEUTICALS COMPANY

ATCコード:

J05AB11

INN（国際名）:

VALACICLOVIR

投薬量:

500MG

医薬品形態:

TABLET

構図:

VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500MG

投与経路:

ORAL

パッケージ内のユニット:

21/42/100/500

処方タイプ:

Prescription

治療領域:

NUCLEOSIDES AND NUCLEOTIDES

製品概要:

Active ingredient group (AIG) number: 0128626001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2018-11-12

製品の特徴

_ _
_ _
_Page 1 of 40_
PRODUCT MONOGRAPH
PR
_CO _VALACYCLOVIR
Valacyclovir Hydrochloride Tablets
500 mg and 1000 mg valacyclovir (as valacyclovir hydrochloride)
Antiviral Agent
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 6J5
Date of Revision:
February 01, 2016
Control No.: 191484
_ _
_ _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 17
STORAGE AND STABILITY
.........................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 19
PART II: SCIENTIFIC INFORMATION
..............................................................................
20
PHARMACEUTICAL INFORMATION
.........................................................................
20
CLINICAL TRIALS
.........................................................................................................
21
DETAILED PHARMACOLOGY
...............